共 50 条
- [31] Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled TrialJOURNAL OF RHEUMATOLOGY, 2013, 40 (04) : 369 - 378Weinblatt, Michael E.Kavanaugh, ArthurGenovese, Mark C.Jones, David A.Musser, Theresa K.Grossbard, Elliott B.Magilavy, Daniel B.
- [32] Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE studyTHERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13Yang, YueXu, JianhuaXu, JianLi, XingfuHu, JiankangLi, XiangpeiZhang, XiaoHe, DongyiBao, ChundeLi, ZhijunWang, GuochunZerbini, Cristiano A. F.Spindler, Alberto J.Kannowski, Carol L.Wu, HanjunJi, FeiZhan, LujingLiu, MengruLi, Zhanguo
- [33] INDIVIDUAL ENTHESEAL POINTS HAVE DIFFERENTIAL FREQUENCY OF INVOLVEMENT AND IMPACT ON PATIENT REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIESANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 220 - 221Coates, L.Mcinnes, I.Aydin, S.Kishimoto, M.Mease, P. J.Shawi, M.Zimmermann, M.Rampakakis, E.Lavie, F.Mcgonagle, D.
- [34] Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trialMODERN RHEUMATOLOGY, 2020, 30 (02) : 313 - 320Tanaka, YoshiyaBass, DamonChu, MyronEgginton, SallyJi, BeulahRoth, David
- [35] Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)QUALITY OF LIFE RESEARCH, 2021, 30 (01) : 105 - 115Ford, JanetTassorelli, CristinaLeroux, ElizabethWang, ShufangAyer, DavidNichols, RussellDetke, Holland
- [36] Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With GalcanezumabHEADACHE, 2018, 58 (08): : 1225 - 1235Ayer, David W.Skljarevski, VladimirFord, Janet H.Nyhuis, Allen W.Lipton, Richard B.Aurora, Sheena K.
- [37] Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)Quality of Life Research, 2021, 30 : 105 - 115Janet FordCristina TassorelliElizabeth LerouxShufang WangDavid AyerRussell NicholsHolland Detke
- [38] DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUSANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1463 - 1463Arriens, C.Askanase, A.Furie, R.Morand, E. F.Van Vollenhoven, R.Connors, K.Davey, M.Delev, N.Shah, V.Stevens, A.Wegman, T.Hobar, C.
- [39] Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorderJOURNAL OF AFFECTIVE DISORDERS, 2022, 308 : 19 - 26Suthoff, EllisonKosinski, MarkArnaud, AlixHodgkins, PaulGunduz-Bruce, HandanLasser, RobertSilber, ChristopherSankoh, Abdul J.Li, HaihongWerneburg, BrianJonas, JeffreyDoherty, JamesKanes, Stephen J.Bonthapally, Vijayveer
- [40] EFFICACY AND SAFETY OF ABBV-599 HIGH DOSE (ELSUBRUTINIB 60 MG AND UPADACITINIB 30 MG) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 91 - 92Merrill, J. T.Tanaka, Y.D'cruz, D.Vila, K.Siri, D.Zeng, X.D'silva, K.Cheng, L.Sornasse, T.Doan, T.Kruzikas, D.Friedman, A.